1. Home
  2. /
  3. Projects

Kenya

Assessing the readiness of communities and civil society to contribute to new TB vaccine policy making and implementation

2024-2026
Hypothetical vaccines
Three-part study to assess the readiness of community and civil society to contribute to TB vaccine policymaking and implementation at national, regional, and global levels, and the investments funders should make to strengthen community capacity and engagement. 1) No Vaccines Without Us: A Global Landscape Analysis of Civil Society Engagement in TB Vaccine Preparedness is based on a global survey of 125 civil society organizations active in the TB response in 42 countries. 2) Country Policy Portraits, written by local activists, illustrate how vaccine policy is made in seven countries — Bangladesh, Kazakhstan, Kenya, Malawi, Mongolia, South Africa, and Vietnam — and propose reforms to strengthen the representation of community partners in national immunization decision making. 3) TB Vaccine Access in “4D”: A Roadmap Charting Civil Society Actions for Equitable Access outlines a series of actions civil society can take to assure access to new TB vaccines along four dimensions: development, delivery, demand, and data.

Tuberculosis Integrated Model-Based Evidence and Recommendations (TIMBER) for robust TB vaccine decision-making by National Immunization Technical Advisory Groups (NITAGs) in Africa.

2025 - 2028
Hypothetical vaccines
The TIMBER study is a multi-country research study aimed at strengthening the use of model-based evidence to support national decision-making on the introduction of new TB vaccines in Africa. The study brings together National Immunization Technical Advisory Groups (NITAGs), policymakers, researchers, modellers and other stakeholders in South Africa, Kenya and The Gambia to co-create models and explore how modelling can be used effectively within the WHO Evidence-to-Recommendation process. TIMBER will generate country-specific evidence, strengthen capacity for using modelling in vaccine policy decisions, and develop practical approaches to support timely, evidence-informed introduction of new TB vaccines.

Facing up to reality? What to do if M72/AS01E doses are limited

M72/AS01e
The Ph3 trial for the vaccine candidate M72/AS01E is underway, and, assuming a positive result, could be licensed by 2030. Modelling suggested a large potential impact from introducing M72/AS01E but assumed an unconstrained dose supply. However, at least initially, it is likely that M72/AS01E will be supply-constrained. We estimated the effect of decisions surrounding the allocation of constrained doses on the potential global impact of M72/AS01E

IAVI

1. Understand likely use cases, delivery strategies, target populations, and drivers of preference and adoption; 2. Project demand; 3. Evaluate potential willingness to pay and budget impact; 4. Explore innovative financing mechanisms;

The potential health and economic impact of introducing the vaccine candidate VPM1002 to prevent tuberculosis disease in low- and middle-income countries

2026
VPM1002
This study estimates the potential health and economic impact of introducing the TB vaccine candidate VPM1002 in 79 low- and middle- income countries. It models routine vaccination and vaccination campaigns, estimating TB cases and deaths averted and the cost-effectiveness of different introduction scenarios. It provides evidence for decisions about the potential future introduction and scale-up of VPM1002
Load More
Click to copy link of this header Menu